Award
National Cancer Institute RFA-CA-22-028
Next generation T cell therapies for mutant KRAS solid tumors
Recipient
Not specified
Award Amount
$2,238,704.00
Ceiling
$2,238,704.00
Awarded
September 19, 2025
Identifier
RFA-CA-22-028
Award for developing next generation T cell therapies targeting mutant KRAS solid tumors, funded by the National Cancer Institute with an estimated value of $2,238,704, active from 2025 to 2028.
Description
This project aims to develop advanced T cell therapies targeting mutant KRAS in solid tumors, leveraging gene editing and biomarker discovery. The award is managed by the National Cancer Institute, with a total budget of approximately $2.24 million for the fiscal year 2025. The project involves multiple investigators and institutions, with a focus on clinical translation and technological innovation.